Eli Lilly and Company introduces ZepboundTM (tirzepatide) injection as a breakthrough in weight management. On November 8, 2023, the FDA approved, marking a significant milestone in the search for effective weight loss solutions. Zepbound brings hope for adults grappling with obesity,…